The University of Chicago Header Logo

Connection

Sarosh Rana to Placenta Growth Factor

Back to Details
This is a "connection" page, showing publications Sarosh Rana has written about Placenta Growth Factor.
Sarosh Rana
Connection Strength
9.807
Placenta Growth Factor
  1. Placental Biomarker Testing for Evaluation of Suspected Preeclampsia. Clin Chem. 2025 May 02; 71(5):548-558.
    View in: PubMed
    Score: 0.861
  2. Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
    View in: PubMed
    Score: 0.844
  3. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
    View in: PubMed
    Score: 0.815
  4. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens. 2021 Mar; 23:97-103.
    View in: PubMed
    Score: 0.634
  5. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022 02; 226(2S):S1019-S1034.
    View in: PubMed
    Score: 0.629
  6. Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
    View in: PubMed
    Score: 0.612
  7. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertens. 2020 Apr; 20:124-130.
    View in: PubMed
    Score: 0.606
  8. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. Pregnancy Hypertens. 2018 Oct; 14:110-114.
    View in: PubMed
    Score: 0.543
  9. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018 Jul; 13:100-106.
    View in: PubMed
    Score: 0.532
  10. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016 Aug; 35(3):330-45.
    View in: PubMed
    Score: 0.458
  11. Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. Am J Clin Pathol. 2025 Aug 26; 164(2):200-206.
    View in: PubMed
    Score: 0.220
  12. Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States. J Appl Lab Med. 2025 Jul 01; 10(4):937-948.
    View in: PubMed
    Score: 0.218
  13. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024 Sep; 231(3):363.e1-363.e11.
    View in: PubMed
    Score: 0.202
  14. Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
    View in: PubMed
    Score: 0.177
  15. Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
    View in: PubMed
    Score: 0.176
  16. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
    View in: PubMed
    Score: 0.170
  17. Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
    View in: PubMed
    Score: 0.169
  18. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.
    View in: PubMed
    Score: 0.163
  19. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Am J Obstet Gynecol MFM. 2021 07; 3(4):100394.
    View in: PubMed
    Score: 0.163
  20. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens. 2018 Jan; 11:66-70.
    View in: PubMed
    Score: 0.129
  21. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Sci Total Environ. 2017 Dec 01; 599-600:2175-2181.
    View in: PubMed
    Score: 0.124
  22. Angiogenic Proteins: Can These Biomarkers Help to Prevent Maternal Deaths Related to Preeclampsia? Hypertension. 2017 03; 69(3):401-403.
    View in: PubMed
    Score: 0.121
  23. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation. 2015 Nov 03; 132(18):1726-33.
    View in: PubMed
    Score: 0.111
  24. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One. 2015; 10(5):e0126815.
    View in: PubMed
    Score: 0.108
  25. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
    View in: PubMed
    Score: 0.106
  26. Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertens Pregnancy. 2014 Nov; 33(4):427-39.
    View in: PubMed
    Score: 0.102
  27. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):643-50.
    View in: PubMed
    Score: 0.097
  28. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013 May; 32(2):189-201.
    View in: PubMed
    Score: 0.094
  29. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One. 2012; 7(10):e48259.
    View in: PubMed
    Score: 0.090
  30. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012 Aug; 60(2):451-8.
    View in: PubMed
    Score: 0.088
  31. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21; 125(7):911-9.
    View in: PubMed
    Score: 0.086
  32. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012; 31(2):211-7.
    View in: PubMed
    Score: 0.085
  33. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022 Dec; 1(12):EVIDoa2200161.
    View in: PubMed
    Score: 0.045
  34. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
    View in: PubMed
    Score: 0.045
  35. Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021 Aug; 25:12-17.
    View in: PubMed
    Score: 0.041
  36. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.028
  37. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014 Feb; 33(1):81-92.
    View in: PubMed
    Score: 0.024
  38. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy. 2014 May; 33(2):250-9.
    View in: PubMed
    Score: 0.024
  39. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013 Sep 01; 41(5):511-6.
    View in: PubMed
    Score: 0.024
  40. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012 Jul; 25(7):1135-41.
    View in: PubMed
    Score: 0.021
  41. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol. 2011 Mar; 204(3):244.e1-12.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.